Aurobindo receives FDA green light for generic Sabril
Vigabatrin for oral solution has an estimated market size of $262.5 million for the 12 months ended July 2021, according to IQVIA.
Aurobindo has received the Food and Drug Administration’s approval for vigabatrin for oral solution, 500mg.
The medication is the generic of Lundbeck’s Sabril.
[Read more: Aurobindo's generic Adalat CC gets FDA OK]
It is indicated as adjunctive therapy for adults and pediatric patients age 10 years old and older with refractory complex partial seizures. It also is indicated as monotherapy for pediatric patients with infantile spasms age 1 month to 2 years old.
[Read more: Aurobindo obtains FDA OK for generic Lioresal]
Vigabatrin for oral solution has an estimated market size of $262.5 million for the 12 months ended July 2021, according to IQVIA.